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Background: Conditional survival (CS) could offer reliable prognostic information for patients who survived beyond
a specified time since diagnosis when the impact of late effects have the greatest influence on prognosis. We aim
to investigate CS for pancreatic ductal adenocarcinoma (PDAC) patients with surgery and nonsurgery.
Methods: Chinese PDAC patients between January 2002 and September 2012 were reviewed for analyses. CS rates
were calculated for survivors after surgery and nonsurgery at different time points.
Results: Several clinicopathologic features were associated with overall survival (OS) in each subgroup including
curative resection, palliative surgery, and nonsurgery. Both univariate and multivariate analyses showed that
chemotherapy was a critical predictor for OS regardless of treatment status. CS rates were higher in the
curative resected patients than other cases at the same time points. Importantly, stratification of 1-year CS by
carcinoembryonic antigen (CEA), (carbohydrate antigen) CA19-9, and tumor stage showed lower CEA, CA19-9,
and tumor stage associated with favorable 1-year CS over time (P = 0.016, 0.009 and 0.003).
Conclusions: Dynamic CS estimates could be an accurate assessment for the prognosis of PDAC patients,
allowing patients and clinicians to project subsequent survival based on time change.
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Pancreas cancer (PC) is a malignant tumor associated
with a high mortality rate and is the fourth commonest
cause of death from cancer worldwide [1–3]. Pancreatic
ductal adenocarcinoma (PDAC) represents about 90 %
of histological subtypes of PC and has high relapse rate
due to unsatisfying diagnostic technology and manage-
ment [4]. Over the past decade, therapeutic options for
PDAC were still limited. Even after undergoing surgery,
chemotherapy or a combination thereof, many patients
who have progressed into advanced cancer before clin-
ical manifestation would succumb to tumor recurrence
or metastasis. Although the mechanisms through which* Correspondence: duchengyou@126.com
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demiological studies have shown that multiple clinical
factors such as carcinoembryonic antigen (CEA) and
carbohydrate antigen 19-9 (CA19-9) [5–7] were likely to
contribute to the increase in the incidence and be re-
lated with the prognosis of PDAC [3, 8–10]. But, for the
studies on the predictive roles of these clinical factors,
most of the investigated patient population were selected
from resectable PDAC. Notably, there are still larger
portions of patients who underwent palliative surgery
without oncologic resection and nonsurgery that owe to
lethal malignancy of PDAC. Therefore, stratifying ana-
lysis by treatment status on the survival and recurrence
of PDAC also needs to be concerned.
However, traditional survival estimates for PDAC
could not always be informative enough, or even mis-
leading, for patients who have survived a period of timele distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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the chance of survival estimates are dynamic, not a static
probability [10–12]. In effect, future survival probability
after resection for PDAC is influenced by clinicopatho-
logical variables based on the time of diagnosis and sur-
gery and likely to change over time. Many previously
published studies [11–13] have also revealed that overall
survival (OS) estimates directly applied to survivors of
PDAC and it rapidly became inaccurate and irrelevant
because of its significant rates of early death and relapse.
Conditional survival (CS) estimates have been identified
as a practical adjunct to traditional survival analysis,
which could offer more accurate and dynamic informa-
tion of postsurgical patients who have survived longer
than expected [14–16]. CS, which calculated the prob-
ability of surviving an additional amount of time given
that the person has already survived to a predefined
period of time after diagnosis and treatment, can update
patients’ prognosis [15]. Although CS estimates for pa-
tients with PDAC have been reported by several investi-
gations [10–13, 17], we noticed that some important risk
factors such as CEA and CA19-9 were not included for
CS analyses and most patients were from Europe and
United States. Also, to the best of our knowledge, there
are currently no published Asian data exploring the CS
pattern of PDAC. In this study, we sought to evaluate
the CS probabilities of Chinese patients with PDAC
stratified by treatment status, which could facilitate to
project subsequent survival over time accrued since
cancer-directed treatment.
Methods
Patient population and data collection
Under the approval of the Ethics Review Committee, be-
tween January 2002 and September 2012, 1208 patients
with PDAC were selected from the First Affiliated Hos-
pital of Chongqing Medical University. This retrospect-
ive cohort study protocol conformed to the ethical
guidelines of the 1975 Helsinki Declaration. Written in-
formed consents were obtained from all patients. Among
these patients, 380 patients underwent pancreaticoduo-
denectomy, distal, or total pancreatectomy. For missing
curative resection opportunities, 348 and 480 patients
were performed by palliative surgical and nonsurgical
treatment, respectively. Their minimum survival time is
at least 30 days. Patients younger than 18 years and
older than 90 years were excluded. Smoking was defined
as ≥1 pack/day for more than 10 years [18], and alcohol-
ism was defined as at least 30 g/day of ethanol [19]. The
American Joint Committee on Cancer (AJCC) staging
system and clinicopathologic data including age, sex,
tumor size, tumor grade, tumor location, lymph node
status, and so on were assessed. Three senior attending
doctors managed the patients who were followed upevery 1–6 months postoperatively according to the post-
operative time with serum CEA and CA19-9 and ab-
dominal computed tomography (CT) and/or magnetic
resonance imaging (MRI).
Statistic analysis
All statistical analyses were completed with SPSS 19.0
(SPSS, Inc., Chicago, IL, USA) and a two-tailed P < 0.05
was considered significant. Results were presented as the
mean ± SD. The Student’s t test was used for comparison
between groups. Clinicopathologic characteristics were
analyzed with Fisher’s exact tests, χ2 tests, and Spearman
ρ coefficients tests. Cumulative event rates and univari-
ate analyses of OS were used by Kaplan-Meier method.
Multivariate Cox proportional hazards model was per-
formed to estimate adjusted hazard ratios (HRs) with a
95 % confidence interval (CI). The cut-off values for
CEA (range, 0–10 ng/ml) and CA19-9 (range, 0–22U/
ml) were determined at two times of upper limit normal
value (ULN) in our hospital.
CS was defined as the probability of surviving an add-
itional y years if the patient has already survived x years.
Therefore, the formula of CS can be expressed as fol-
lows: CS(y/x) = S(x + y)/Sx, where x represents years sur-
vived and y stands for additional years [10, 11]. Given
the aggressive natural history of PDAC and most of its
median, survival after curative surgery is within 1 year
[10, 12, 20, 21]; 1-year and 6-month CS for curative
resected patients were calculated in the current study.
Mathematically, the formula should be expressed as fol-
lows: CS(y/1) = S(1+y)/S1. Similarly, 3-month and 6-month
CS were used for analyses of patients with palliative sur-
gery and nonsurgery. Actual survival was the interval




The baseline characteristics of 1208 Chinese patients
with PDAC are described in Table 1. In all, the median
age was 63 years (range, 21–88 years) with 736 men and
472 women. The most common presenting symptom
was abdominal distention or pain (55 %) followed by
jaundice (29.8 %). Few patients have no any symptom
(9.9 %) and weight loss (5.3 %). Of the 1208 incident of
PDAC cases, some patients had adverse lifestyles and
diseases including smoking history (n = 448, 37.1 %), al-
coholism (n = 256, 21.2 %), and diabetes (n = 264, 21.9
%). All patients were divided into three subgroups ac-
cording to treatment status: curative resection, palliative
surgery, and nonsurgery. At the time of surgery, 31.5 %
(n = 380) of patients underwent curative resection
including pancreaticoduodenectomy (n = 300), distal
pancreas (n = 64), and total pancreatectomy (n = 16).




(n = 480)curative (n = 380) Palliative (n = 348)
Age (median) 63 61 63 64
Gender (male) 736 (60.9 %) 232 (61.1 %) 248 (71.3 %) 256 (53.3 %)
Smoking (yes) 448 (37.1 %) 148 (38.9 %) 160 (46.0 %) 140 (29.2 %)
Diabetes (yes v no) 256 (21.2 %) 52 (13.7 %) 96 (27.6 %) 116 (24.2 %)
Alcoholism (yes v no) 256 (21.2 %) 80 (21.1 %) 96 (27.6 %) 80 (16.7 %)
Chief complaint
No symptom 120 (9.9 %) 68 (17.9 %) 8 (2.3 %) 44 (9.2 %)
Abdominal distention/pain 664 (55 %) 172 (45.3 %) 184 (52.9 %) 308 (64.2 %)
Jaundice 360 (29.8 %) 128 (33.7 %) 148 (42.5 %) 84 (17.5 %)
Weight loss 64 (5.3 %) 12 (3.2 %) 8 (2.3 %) 44 (9.2 %)
Tumor characteristics
Tumor size (≤2) 192 (15.9 %) 80 (21.1 %) 56 (16.1 %) 56 (11.7 %)
Tumor number (single) 1176 (97.4 %) 364 (95.8 %) 340 (97.7 %) 472 (98.3 %)
Tumor encapsulation (yes) – 284 (74.7 %) 212 (60.9 %) –
Tumor location (head) 856 (70.9 %) 284 (74.7 %) 340 (97.7 %) 232 (48.3 %)
Tumor differentiation (I–II) – 276 (72.6 %) 148 (42.5 %) –
Lymph nodes positive (yes) – 84 (22.1 %) 96 (27.6 %) –
AJCC stage (I–II) 512 (42.4 %) 300 (78.9 %) 136 (39.1 %) 76 (15.8 %)
CEA (≤2ULN) 924 (76.5 %) 296 (77.9 %) 292 (83.9 %) 336 (70.0 %)
CA19-9 (≤2ULN)k 316 (26.2 %) 164 (43.2 %) 72 (20.1 %) 80 (16.7 %)
Chemotherapy (yes) 892 (73.8 %) 324 (85.3 %) 308 (88.5 %) 260 (54.2 %)
Tumor differentiation: I, Well differentiated; II, moderately differentiated; III, poorly differentiated; and IV, undifferentiated
AJCC American Joint Committee on Cancer staging system, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9. ULN Upper Limit of Normal. ULN of
CEA and CA19-9 are 10 ng/ml and 22U/ml
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receive the oncologic resections which have no any
influence on their survival. For the patients (n = 480)
who refused surgery or/and missed the operative
opportunities, chemotherapy, radiotherapy, high inten-
sity focused ultrasound, and other nonsurgical treatment
had been administered. A substantially higher percentage
of patients (73.5 %) were performed with chemotherapy.
Correlation of clinicopathologic features and overall survival
For the whole investigated cohort, median survival of
PDAC following treatment was 12.8 months (range, 1–67
months) with an observed 6 months, 1-, 2-, and 3-year sur-
vival rates were 64, 42, 27, and 21 %, respectively. Obvi-
ously, curative resected cases (21.6 ± 12.2 months) had
better prognosis than palliative surgical (10.5 ± 7.5 months)
and nonsurgical patients (6 ± 5.5 months). Table 2 presents
the results of cox regression analyses by surgical and non-
surgical treatment. Some clinicopathologic features were
associated with OS in each subgroup. Importantly, chemo-
therapy was shown as a critical prognosis related factor
after both surgery and nonsurgery. On univariate analyses,
CEA and CA19-9 had associations with survival other thanage, tumor differentiation, and lymph node status in sur-
gery groups (curative resection and palliative surgery).
Tumor stage and tumor size were significant risk factors
with the outcome of PDAC after curative resection. Tumor
encapsulation and different tumor location correlated with
survival of palliative surgical patients. Moreover, CEA,
tumor stage, and tumor location also showed predictive
value for the outcome of nonsurgical patients with PDAC.
Then, competing clinical risk factors were used for further
multivariate analyses. Different variables showed significant
discrepancy in OS in three subgroups, respectively. For ex-
ample, poor tumor differentiation and lymph nodes metas-
tasis deem to worsen survival for curative resected patients.
While after palliative surgery, older patients, higher CEA,
and no tumor encapsulation were independent predictors
for OS. In addition, the prognostic abilities of tumor stage
and CEA could also be applied to patients with nonsurgical
treatment.
Conditional survival
Table 3 depicts the results of CS probabilities given that
patients have already survived 6 to 36 months in 6-
month intervals after treatment. Compared to actual
Table 2 Results of cox regression analyses by surgical and nonsurgical treatment
Factors Curative resection Palliative surgery Nonsurgery
Univariate Multivariate Univariate Multivariate Univariate Multivariate
P HR (95 % CI) P P HR (95 % CI) P P HR (95 % CI) P
Age (≤63 v >63) 0.041 0.267 0.002 2.064
(1.222–3.485)
0.007 0.719 NA
Gender (male v female) 0.604 NA 0.411 NA 0.178 NA
Smoking (yes v no) 0.509 NA 0.188 NA 0.902 NA
Diabete (yes v no) 0.976 NA 0.096 NA 0.208 NA
Alcoholism (yes v no) 0.112 NA 0.388 NA 0.723 NA
Tumor size (≤2 v >2) 0.014 0.467 0.283 NA 0.609 NA
Tumor number (single v multiple) 0.143 NA 0.355 NA 0.538 NA
Tumor encapsulation
(yes v no)
0.208 NA <0.001 3.799
(2.147–6.723)
<0.001 NA NA
Tumor location (head v body/
distal/multifocal)










0.010 0.005 0.307 NA NA
AJCC stage (I–II v III–IV) 0.010 0.764 0.892 NA 0.009 1.405 (1.080–1.828) 0.011
CEA (≤2ULN v >2ULN) 0.013 0.078 0.001 3.568
(1.751–7.269)
<0.001 0.006 1.600 (1.054–2.428) 0.027
CA19-9 (≤2ULN v >2ULN) 0.033 0.339 <0.001 0.066 0.525 NA




<0.001 <0.001 5.118 (3.209–8.162) <0.001
Univariate analysis: Kaplan-Meier method; multivariate analysis: Cox proportional hazards regression model
CR curative resection, IR incurative resection, UR unresection; Tumor differentiation I: Well differentiated; II: moderately differentiated; III: poorly differentiated; and
IV: undifferentiated, AJCC American Joint Committee on Cancer staging system, CEA carcinoembryonic antigen; CA19-9 carbohydrate antigen 19-9, NA not adopted
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tients in each group whether surgery had been received
or not. For example, whereas the actuarial survival at 12
months after curative resection, palliative surgery, and
nonsurgery were 77.9, 36.8, and 15.8 %, respectively, the
6-month CS at 6 months, that is postoperative month 6
(to a total of 12), increased to 83.1, 49.3, and 44.1, re-
spectively. Consistent to actual survival, higher CS rates
were observed in the patients who underwent curative





Time elapsed after surgery and
6 months 12 mon
6 months 93.7/74.7/35.8 –
12 months 77.9/36.8/15.8 83.1/49.3/44.1 –
18 months 61.1/13.8/5.8 65.2/18.5/16.2 78.4/37.
24 months 41.1/4.6/1.7 43.9/6.2/4.7 52.8/12.
30 months 22.1/4.6/NA 23.6/6.2/NA 28.4/12.
36 months 20.0/NA/NA 21.3/NA/NA 25.7/NA
CR curative resection, PS palliative surgery, NS nonsurgery, NA not adopted for all p
aIf a patient with curative resection has already survived for 6 months, the 6-monthand nonsurgery at the same time points. Following cura-
tive resection, survival at 2 years after surgery was 41.1
% compared with the 12-month conditional survival of
52.8 % after having survived 12 months. Although the 1-
year actual survival of the patients after palliative surgery
and nonsurgery were very dismal (36.8 and 15.8 %), the
6-month CS at 6 months (to a total of 1 year) still sub-
stantially arrived at 49.3 and 44.1 %, respectively.
To further evaluate the predictive value of some im-
portant clinicopathologic features, CS was then stratifiedatic ductal adenocarcinoma survived for additional time (%)
nonsurgery (CR/PS/NS)
ths 18 months 24 months 30 months
5/36.7 –
5/10.8 67.3/33.3/29.3 –
5/NA 36.2/33.3/NA 53.8/NA/NA –
/NA 32.7/NA/NA 48.7/NA/NA 90.5/NA/NA
atients died in the subgroup
conditional survival is 83.1 %
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and 1-year landmark after recurative resection. The
patients with lower CEA (P = 0.016) and CA19-9 (P =
0.009) had higher CS. If the patients have developed into
advanced stage (III), those patients who did survive to
the 15-month mark, more likely had poorer CS (P =
0.003). However, because of the extremely poor progno-
sis of palliative surgical and nonsurgical patients with
PDAC (medians, 8 and 4 months, respectively), CS is
not a highly valuable tool to predict the outcome of
these patients over time stratifying by lower (stage II and
III) and higher (stage IV) stages (both P > 0.05).
Discussion
In the last years, despite tremendous research activities
of tumor-specific therapy, PDAC survival is fairly dismal
[3]. Hence, analyses of survival outcome and related risk
factors have the clinical importance to establish risk no-
mograms of PDAC which could provide quantitative
information for general comparisons and treatment se-
lection. The routine use of CS estimates was strongly
recommended by more and more clinicians and re-
searchers because it provided more reliable dynamic
prognostic information over time for cancer survivors
[10–12]. In this study, we also found PDAC CS probabil-
ities improved over time for all patients based on the
additional years already survived by them, no matter
what kind of treatment was performed. Furthermore, CS
estimates would be more suitable for the patients after
curative resection than the population that underwent
palliative surgery and nonsurgery due to their very short
period of OS, particularly when it was stratified by some
clinicopathologic features (e.g., tumor stage, CEA,
CA19-9, et al.) for further evaluation of the predictive
value of CS.
It is important to know how the chances of long-term
survival improve for patients with PDAC after different
treatment which can reflect treatment response and out-
come from treatment. Predictive accuracy will benefitFig. 1 One-year conditional of patients with pancreatic ductal adenocarcin
tumor stage. a One-year CS by CEA (cut-off value, 20 ng/ml); b One-year C
III. The x-axis represents the time after curative resectionfor our clinical decision-making in a more realistic man-
ner, especially for patients who have survived a period of
time beyond surgery or any other nonsurgical treatment.
Our study showed that CS estimates could assess the
prognosis by dynamic analysis on changing survival ex-
pectations of patients with PDAC over time regardless
of any treatment. Previously, CS has already been ap-
plied in the prognosis estimate of PDAC in several stud-
ies [10–13]; however, we found that the majority of
patients in the ethnic groups belong to Europe,
Australia, and United States, and these investigations fo-
cused on the relationship between tumor characteristic
and survival of patients with PDAC. For the first time,
we analyzed CS of patients with PDAC in Chinese Han
population and also explored CS stratified by tumor
markers such as CEA and CA19-9. For those patients
who underwent curative resection, lower CEA and
CA19-9 afforded better CS to the 1-year mark. In fact,
the predictive roles of CEA and CA19-9 for OS of PDAC
after curative resection have been demonstrated before
[5–7]. This may suggest that CEA and CA19-9 derived
from cancer cells are involved in the development of
PDAC. Therefore, with decreased serum levels of CEA
and CA19-9 after tumor remove, CS will continue to im-
prove when time goes on.
PDAC is a very lethal malignancy which is always diag-
nosed in a symptomatic phase and thus too late to be
resected. Several reports about CS of PDAC investigated
the patients after curative resection and unresection
[10–12], majority of whom belong to stage I and IV. Ac-
tually, there still are larger portions of patients who
underwent palliative surgery without oncologic resec-
tion, whose CS remain to be known. As known, treat-
ment is one of the critical factors to influence CS
estimates. Accordingly, the patients in our study were
divided into three subgroups by surgical approaches or
whether performing operation. For curative resected pa-
tients, their CS probabilities and the absolute improve-
ment in CS are much better than those patients withoma (PDAC) after curative resection stratified (CS) by CEA, CA19-9, and
S by CA19-9 (cut-off value, 44U/ml); c One-year CS by stages I through
Liao et al. World Journal of Surgical Oncology  (2015) 13:196 Page 6 of 7palliative surgery and nonsurgery. On the other hand,
compared to nonsurgery subgroup, CS probabilities of
patients with palliative surgery are slightly higher
(Table 3). These results should be attributed to the tem-
porary improvement of cancer biology after tumor re-
moval, and thus, patients obtain better quality of life. In
addition, the purpose of CS calculations is modulation
of survival estimates and equation of actual survival by
long-term follow-up. At this point, for the patients with
palliative surgery and nonsurgery, tumor stage could not
accurately reflect their CS by stratify analysis because
most of these patients are in advanced stage and have
higher recurrence risk and subsequently far shorter sur-
vival (<6 months). However, patients with advanced
stage would still get better CS than actual survival when
they survived for a longer time.
We also found that some adverse lifestyles and disease
such as smoking, alcoholism, and diabetes had no rela-
tionship with the prognosis of OS, despite that they are
important risk factors of PDAC onset and progression
[3, 22, 23]. We speculated that after diagnosis and treat-
ment, improvement of diabetes mellitus and quitting
smoking and alcohol could benefit the outcome of
PDAC. In three subgroups, different clinicopathologic
features showed associations with OS. The reason for
the discrepancy may be partly due to features of the can-
cer biology that are different in various tumor stages.
Further knowledge about these individual cancer biology
features needs studies of mechanism in depth. Notably,
our analyses revealed that chemotherapy was shown as a
critical prognosis related factor after both surgery and non-
surgery. Many clinicians recommend surgery followed by
adjuvant treatment; however, the application of optimal
chemotherapy alone or after surgery remains unclear and
controversial [24–26]. We believe that comprehensive basic
studies and clinic trials on chemotherapy need to be con-
ducted appropriately.
Here, we acknowledge several limitations to the
current analyses. The simple size is still far from great.
Additionally, for the patients without cancer-directed
surgery, we could not obtain the accurate data of tumor
differentiation and tumor encapsulation in the absence
of a pathologic specimen; also, tumor stage partly de-
pends on the analysis from CT and/or MRI scanning. In-
deed, majority of these patients are in advanced stage
and have similar survival estimates. Furthermore, our
analysis stratifying by treatment status did find the dif-
ference of CS. We hope to provide supplementary infor-
mation for the generalizability of CS application by these
investigation results from Chinese Han population of pa-
tients diagnosed with PDAC in a single cancer center.
From the current study, we could have better under-
standing for administration of chemotherapy for the
prognosis of survival in PDAC. It is not available inSurveillance, Epidemiology, and End Results (SEER)
database, although from which we can get large patient
population.
Conclusions
In conclusion, we have shown that CS could provide re-
liable estimation of future survival for survivors of
PDAC after treatment at multiple time points. Moreover,
stratifying analyses suggested that CS could be applied
in the patients with curative resection more suitably
than those treated by palliative surgery and nonsurgery.
Also, CEA and CA19-9, related with OS and CS prob-
abilities of the patients with curative resection, should
be considered for prognostic nomograms of PDAC.
Thus, separate CS estimates by treatment status may be
a useful measure to allow clinicians to constantly adjust
the treatment for the patients and project subsequent
survival based on time change. Furthermore, ongoing
study of the use of chemotherapy is required to make.
This tool may help us make appropriate decisions for
triaging at-risk patients choosing treatment approaches
and have significant effects on the quality of life of survi-
vors of PDAC.
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